As LDT developers await an FDA decision on potential new regulations and grapple with reimbursement issues, investors may be unwilling to deal with the uncertainty.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
OpGen attributed the rise to sales of infectious disease diagnostics products from its AdvanDx acquisition and lab services based on the Acuitas MDRO suite.
The infectious disease diagnostics and bioinformatics firm will use the money for sales, marketing, R&D, and general corporate purposes a year after going public.
